GAD-65 ANTIBODY (PARANEOPLASTIC SYNDROME), SERUM

image not found

NABL Cap Accredited    
The GAD-65 Antibody test detects autoantibodies against the glutamic acid decarboxylase enzyme, often associated with paraneoplastic neurological syndromes and autoimmune diabetes. Metropolis Healthcare performs this test using advanced immunoassay methods to ensure precise detection. It helps clinicians identify autoimmune activity, evaluate neurological symptoms, and monitor disease progression. Early detection aids in diagnosis and management of paraneoplastic and autoimmune conditions 

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 7,000.00

Sample Type: SERUM

Fasting Not Required


Notes: G0058

Frequently Asked Questions (FAQ's):

What does the GAD-65 Antibody test detect?
It identifies autoantibodies against GAD-65, indicating autoimmune or paraneoplastic activity.

Who should take this test?
Patients with unexplained neurological symptoms, suspected paraneoplastic syndrome, or autoimmune diabetes.

What sample is required?
A serum sample collected through a routine blood draw.

Do I need to fast before the test?
No fasting is required for GAD-65 antibody testing.

How does Metropolis Healthcare perform this test?
Metropolis uses sensitive immunoassay technology for accurate antibody detection.

Can this test confirm a paraneoplastic syndrome?
It supports diagnosis but must be interpreted alongside clinical findings and other investigations.

How soon are results available at Metropolis Healthcare?
Reports are usually available within a short turnaround time for timely clinical assessment.

Why is early detection important?

It helps initiate prompt treatment, manage autoimmune responses, and monitor neurological progression 

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab